---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-092626"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2024-08-26T23:59:59+00:00"
generated_at: "2026-05-31T07:46:54.770768+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Armata reports diSArm trial 80% enrolled, AP-PA02 topline data Sep 2024; Phase 3 planned for 2025

## Summary
- diSArm Phase 1b/2a for AP-SA02 (S. aureus bacteremia) now 80% enrolled; completion expected Q4 2024.
- AP-PA02 (P. aeruginosa bronchiectasis) enrollment completed; topline data expected September 2024.
- Intravenous AP-SA02 and inhaled AP-PA02 well tolerated; early data show phage activity and persistence.
- Phage candidates planned to enter pivotal Phase 3 trials in 2025, supported by $21.6M DoD grant.
- Inhaled AP-PA02 monotherapy showed comparable to better bacterial load reduction vs antibiotics in blinded data.

## SEC filing metadata
- accession: 0001104659-24-092626
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2024-08-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465924092626/0001104659-24-092626-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465924092626/tm2422583d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-092626
- JSON: https://secwatch.observer/filing/0001104659-24-092626.json
- Plain text: https://secwatch.observer/filing/0001104659-24-092626.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.